EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Structure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy

Soumitra Guin, José E Teixeira, Peter Miller, Ankita Sarkar, Christopher D Huston iD, Marvin J Meyers iD

Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 19355-19370

DOI: 10.1021/acs.jmedchem.6c01707 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 27.07.2026. Verfasst von Soumitra Guin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Saint Louis University, Saint Louis, Missouri63103, United States. Hauptthemen laut MEDLINE: Boron Compounds, Cryptosporidiosis, Antiprotozoal Agents, Cryptosporidium. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cryptosporidiosis is a major cause of life-threatening diarrhea in children and chronic diarrhea in immunocompromised individuals. Our previous work identified pyrazolo[3,4-d]pyrimidine benzoxaborole (2) as an orally efficacious inhibitor of Cryptosporidium with a downside of relapse after 7 days post drug treatment. Here, we report a structure–activity relationship study around the benzoxaborole ring of compound 2, resulting in rac- 11 with improved in vitro potency (EC50 = 0.025 μM). Remarkably, rac- 11 is noncytotoxic and displayed curative in vivo efficacy in Cryptosporidium-infected immunocompromised NSG mice. Furthermore, resolution of rac-11 into its enantiomers demonstrated that one enantiomer is 2-fold more potent (ent2-11; EC50 = 0.011 μM), whereas the other is 400-fold less potent, highlighting the importance of the methyl group at the C3 position of benzoxaborole. The ent2-11 also had reduced adverse binding to hPDE5 compared to 2. Collectively, these findings advance new and effective candidates for the treatment of cryptosporidiosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Boron CompoundsCryptosporidiosisAntiprotozoal AgentsCryptosporidiumStructure-Activity RelationshipAnimalsMiceHumansStereoisomerism

Substanzen

Boron CompoundsAntiprotozoal Agents

Autor:innen und Institutionen

  • Department of Chemistry, Saint Louis University, Saint Louis, Missouri63103, United States.
  • Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont05401, United States.
  • Institute for Drug and Biotherapeutic Innovation, Saint Louis University, St. Louis, Missouri63103, United States.

ORCID-Profile: Christopher D Huston, Marvin J Meyers

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Guin, S., Teixeira, J. E., Miller, P., Sarkar, A., Huston, C. D., & Meyers, M. J. (2026). Structure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy. Journal of Medicinal Chemistry, 69(15), 19355-19370. https://doi.org/10.1021/acs.jmedchem.6c01707

Vancouver

Guin S, Teixeira JE, Miller P, Sarkar A, Huston CD, Meyers MJ. Structure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy. Journal of Medicinal Chemistry. 2026;69(15):19355-19370. doi:10.1021/acs.jmedchem.6c01707

BibTeX
@article{Guin2026,
  author = {Guin, Soumitra and Teixeira, José E and Miller, Peter and Sarkar, Ankita and Huston, Christopher D and Meyers, Marvin J},
  title = {Structure–Activity Relationship Study of Anti- Cryptosporidium Benzoxaboroles Yields Enhanced Potency and Curative Efficacy},
  journal = {Journal of Medicinal Chemistry},
  year = {2026},
  volume = {69},
  number = {15},
  pages = {19355--19370},
  doi = {10.1021/acs.jmedchem.6c01707}
}
Kostenlos starten →